The Moderna Laboratory has begun the so-called phase 1 trial stage of an HIV vaccine using messenger RNA technology in the United States, on 56 uninfected adults, both the biotech company and the ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), ...

As proven by the success of the Spikevax COVID-19 vaccine, Moderna aims to build on this ... This includes vaccines for norovirus and cytomegalovirus, with data readouts expected this year.

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ ... respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical ...